KCG
TCRT icon

Knight Capital Group’s Alaunos Therapeutics TCRT Stock Holding History

Knight Capital Group’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q2 		$52K Buy
+164
New +$45.5K ﹤0.01% 3056

Other funds holding TCRT

TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return

Knight Capital Group's TCRT Position: Q2 2013 in Review

Knight Capital Group opened a new position in Alaunos Therapeutics (TCRT) in Q2 2013: 164 shares worth $52K. The stake represents ﹤0.01% of the portfolio and ranks #3056 among its holdings.

70 funds tracked by Wall St. Rank hold TCRT as of Q2 2013.

  • Knight Capital Group held 164 shares of Alaunos Therapeutics worth $52K as of Q2 2013.
  • Alaunos Therapeutics was a new Knight Capital Group position in Q2 2013.
  • Alaunos Therapeutics made up ﹤0.01% of Knight Capital Group's portfolio in Q2 2013, its #3056 holding.
  • 70 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2013.

Based on Knight Capital Group's 13F filing for Q2 2013, filed 8 Aug 2013.